Influence of PET/CT on radiologists and contrast-enhanced CT on nuclear medicine physicians in patients with lymphoma

Quarterly Journal of Nuclear Medicine and Molecular Imaging

Volumn 55, Issue 3, 2011, Pages 324-333

  Ouvrier, M J ^a,b   Diologent, B ^a   Edet Sanson, A ^a,b   Callonnec, F ^a   Hitzel, A ^a,b   Pesquet, A S ^a   Hapdey, S ^a,b   Modzelewski, R ^a,b   Thillays, M ^a   Menard, J F ^b   Jardin, F ^a   Tilly, H ^a   Vera, P ^a,b  

^a CENTRE HENRI BECQUEREL   (France)

^b ROUEN UNIVERSITY HOSPITAL   (France)

Author keywords

Diagnostic imaging; Fluodeoxyglucose F18; Lymphoma; Tomography, emission computed

Indexed keywords

ANTINEOPLASTIC AGENT; FLUORODEOXYGLUCOSE F 18;

ADULT; ARTICLE; CANCER STAGING; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; HODGKIN DISEASE; HUMAN; INTERMETHOD COMPARISON; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; NONHODGKIN LYMPHOMA; POSITRON EMISSION TOMOGRAPHY;

ADULT; AGED; CONTRAST MEDIA; FEMALE; HODGKIN DISEASE; HUMANS; LYMPHOMA; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; NUCLEAR MEDICINE; OBSERVER VARIATION; POSITRON-EMISSION TOMOGRAPHY; RADIOGRAPHIC IMAGE INTERPRETATION, COMPUTER-ASSISTED; RADIOLOGY; TOMOGRAPHY, X-RAY COMPUTED;

EID: 79960972121     PISSN: 18244785     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Beyer T, Townsend DW, Brun T, Kinahan PE, Charron M, Roddy R et al. A combined PET/CT scanner for clinical oncology. J Nucl Med 2000;41:1369-79. (Pubitemid 30643379)
2. Collins CD. PET in lymphoma. Cancer Imaging 2006;6:S63-70.
3. Kostakoglu L, Leonard JP, Coleman M, Goldsmith SJ. The role of FDG-PET imaging in the management of lymphoma. Clin Adv Hematol Oncol 2004;2:115-21.
4. Jhanwar YS, Straus DJ. The role of PET in lymphoma. J Nucl Med 2006;47:1326-34. (Pubitemid 47544887)
5. Lowe VJ, Wiseman GA. Assessment of lymphoma therapy using (18)F-FDG PET. J Nucl Med 2002;43:1028-30.
6. Schoder H, Meta J, Yap C, Ariannejad M, Rao J, Phelps ME et al. Effect of whole-body (18)F-FDG PET imaging on clinical staging and management of patients with malignant lymphoma. J Nucl Med 2001;42:1139-43.
7. Seam P, Juweid ME, Cheson BD. The role of FDG-PET scans in patients with lymphoma. Blood 2007;110:3507-16. (Pubitemid 350159614)
8. Newman JS, Francis IR, Kaminski MS, Wahl RL. Imaging of lymphoma with PET with 2-[F-18]-fluoro-2-deoxy-D-glucose: correlation with CT. Radiology 1994;190:111-6.
9. Stumpe KD, Urbinelli M, Steinen HC, Glanzmann C, Buck A, von Schulthess GK. Whole-body positron emission tomography using fluorodeoxyglucose for staging of lymphoma: effectiveness and comparison with computed tomography. Eur J Nucl Med 1998;25:721-8. (Pubitemid 28377035)
10. Surbone A, Longo DL, DeVita VT Jr, Ihde DC, Duffey PL, Jaffe ES et al. Residual abdominal masses in aggressive non-Hodgkin's lymphoma after combination chemotherapy: significance and management. J Clin Oncol 1988;6:1832-7. (Pubitemid 19089065)
11. Janicek M, Kaplan W, Neuberg D, Canellos GP, Shulman LN, Shipp MA. Early restaging gallium scans predict outcome in poor-prognosis patients with aggressive non-Hodgkin's lymphoma treated with high-dose CHOP chemotherapy. J Clin Oncol 1997;15:1631-7. (Pubitemid 27167403)
12. Salloum E, Brandt DS, Caride VJ, Cornelius E, Zelterman D, Schubert W et al. Gallium scans in the management of patients with Hodgkin's disease: a study of 101 patients. J Clin Oncol 1997;15:518-27. (Pubitemid 27074218)
13. Kostakoglu L, Leonard JP, Kuji I, Coleman M, Vallabhajosula S, Goldsmith SJ. Comparison of fluorine-18 fluorodeoxyglucose positron emission tomography and Ga-67 scintigraphy in evaluation of lymphoma. Cancer 2002;94:879-88. (Pubitemid 34150840)
14. Kostakoglu L, Goldsmith SJ. Fluorine-18 fluorodeoxyglucose positron emission tomography in the staging and follow-up of lymphoma: is it time to shift gears? Eur J Nucl Med 2000;27:1564-78.
15. Antoch G, Freudenberg LS, Beyer T, Bockisch A, Debatin JF. To enhance or not to enhance? 18F-FDG and CT contrast agents in dual-modality 18F-FDG PET/CT. J Nucl Med 2004;45(Suppl 1):56S-65S.
16. Antoch G, Freudenberg LS, Stattaus J, Jentzen W, Mueller SP, Debatin JF et al. Whole-body positron emission tomographyCT: optimized CT using oral and IV contrast materials. AJR Am J Roentgenol 2002;179:1555-60. (Pubitemid 35386660)
17. Berthelsen AK, Holm S, Loft A, Klausen TL, Andersen F, Hojgaard L. PET/CT with intravenous contrast can be used for PET attenuation correction in cancer patients. Eur J Nucl Med Mol Imaging 2005;32:1167-75. (Pubitemid 41355943)
18. Beyer T, Antoch G, Bockisch A, Stattaus J. Optimized intravenous contrast administration for diagnostic whole-body 18F-FDG PET/CT. J Nucl Med 2005;46:429-35. (Pubitemid 43093151)
19. Brechtel K, Klein M, Vogel M, Mueller M, Aschoff P, Beyer T et al. Optimized contrast-enhanced CT protocols for diagnostic whole-body 18F-FDG PET/CT: technical aspects of single-phase versus multiphase CT imaging. J Nucl Med 2006;47:470-6. (Pubitemid 46768489)
20. Mawlawi O, Erasmus JJ, Munden RF, Pan T, Knight AE, Macapinlac HA et al. Quantifying the effect of IV contrast media on integrated PET/CT: clinical evaluation. AJR Am J Roentgenol 2006;186:308-19. (Pubitemid 46100297)
21. Pfannenberg AC, Aschoff P, Brechtel K, Muller M, Klein M, Bares R et al. Value of contrast-enhanced multiphase CT in combined PET/CT protocols for oncological imaging. Br J Radiol 2007;80:437-45. (Pubitemid 47322230)
22. Yau YY, Chan WS, Tam YM, Vernon P, Wong S, Coel M et al. Application of intravenous contrast in PET/CT: does it really introduce significant attenuation correction error? J Nucl Med 2005;46:283-91.
23. Vera P, Ouvrier MJ, Hapdey S, Thillays M, Pesquet AS, Diologent B et al. Does chemotherapy influence the quantification of SUV when contrast-enhanced CT is used in PET/CT in lymphoma? Eur J Nucl Med Mol Imaging 2007;34:1943-52. (Pubitemid 350212124)
24. Winkler NT. ALARA concept-now a requirement. Radiol Technol 1980;51:525.
25. Jessen K, Panzer W, Shrimpton P. EUR 16262. European guidelines on quality criteria for computed tomography. Office for Official publications of the European communities; 2000.
26. Schaefer NG, Hany TF, Taverna C, Seifert B, Stumpe KD, von Schulthess GK et al. Non-Hodgkin lymphoma and Hodgkin disease: coregistered FDG PET and CT at staging and restaging-do we need contrast-enhanced CT? Radiology 2004;232:823-9. (Pubitemid 39100269)
27. Antoch G, Jentzen W, Freudenberg LS, Stattaus J, Mueller SP, Debatin JF et al. Effect of oral contrast agents on computed tomography-based positron emission tomography attenuation correction in dual-modality positron emission tomography/ computed tomography imaging. Invest Radiol 2003;38:784-9. (Pubitemid 37444951)
28. Nakamoto Y, Chin BB, Kraitchman DL, Lawler LP, Marshall LT, Wahl RL. Effects of nonionic intravenous contrast agents at PET/CT imaging: phantom and canine studies. Radiology 2003;227:817-24. (Pubitemid 36583042)
29. Rodriguez-Vigil B, Gomez-Leon N, Pinilla I, Hernandez-Maraver D, Coya J, Martin-Curto L et al. PET/CT in lymphoma: prospective study of enhanced full-dose PET/CT versus unenhanced low-dose PET/CT. J Nucl Med 2006;47:1643-8. (Pubitemid 47545030)
30. Hutchings M, Loft A, Hansen M, Pedersen LM, Buhl T, Juriander J et al. FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. Blood 2006;107:52-9. (Pubitemid 43053523)
31. Weber WA. Use of PET for monitoring cancer therapy and for predicting outcome. J Nucl Med 2005;46.983-95.
32. Mikhaeel NG, Hutchings M, Fields PA, ODoherty MJ, Timothy AR. FDG-PET after two to three cycles of chemotherapy predicts progression-free and overall survival in high-grade non-Hodgkin lymphoma. Ann Oncol 2005;16:1514-23. (Pubitemid 41222425)
33. Juvveid ME, Wiseman GA, Vose JM, Ritchie JM, Menda Y, Wooldridge JE et al. Response assessment of aggressive non-Hodgkin's lymphoma by integrated International Workshop Criteria and fluorine-18-fluorodeoxyglucose positron emission tomography. J Clin Oncol 2005;23:4652-61. (Pubitemid 46224067)
34. Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007;25:579-86. (Pubitemid 350002966)
35. Juweid ME, Stroobants S, Hoekstra OS, Mottaghy FM, Dietlein M, Guermazi A et al. Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol 2007;25:571-8. (Pubitemid 350002965)
36. Reske SN. PET and restaging of malignant lymphoma including residual masses and relapse. Eur J Nucl Med Mol Imaging 2003;30(Suppl 1):S89-96.
37. Jerusalem G, Beguin Y, Fassotte MF, Belhocine T, Hustinx R, Rigo P et al. Early detection of relapse by whole-body positron emission tomography in the follow-up of patients with Hodgkin's disease. Ann Oncol 2003;14:123-30. (Pubitemid 36150270)
38. Mikhaeel NG, Timothy AR, Hain SF, ODoherty MJ. 18-FDG-PET for the assessment of residual masses on CT following treatment of lymphomas. Ann Oncol. 2000;11(Suppl 1):147-50.
39. Osman MM, Cohade C, Fishman EK, Wahl RL. Clinically significant incidental findings on the unenhanced CT portion of PET/CT studies: frequency in 250 patients. J Nucl Med 2005;46:1352-5. (Pubitemid 43733487)
40. Gollub MJ, Hong R, Sarasohn DM, Akhurst T. Limitations of CT During PET/CT. J Nucl Med 2007;48:1583-91.